Promising early outcomes with a novel, complete steroid avoidance immunosuppression protool in pediatric renal transplantation

被引:156
作者
Sarwal, MM
Yorgin, PD
Alexander, S
Millan, MT
Belson, A
Belanger, N
Granucci, L
Major, C
Costaglio, C
Sanchez, J
Orlandi, P
Salvatierra, O
机构
[1] Stanford Univ, Sch Med, Med Ctr, Dept Pediat, Palo Alto, CA 94304 USA
[2] Stanford Univ, Sch Med, Dept Surg, Palo Alto, CA 94304 USA
关键词
D O I
10.1097/00007890-200107150-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Corticosteroids have been a corner-stone of immunosuppression for four decades despite their adverse side effects. Past attempts at steroid withdrawal in pediatric renal transplantation have had little success. This study tests the hypothesis that a complete steroid-free immunosuppressive protocol avoids steroid dependency for suppression of the immune response with its accompanying risk of acute rejection on steroid withdrawal. Methods. An open labeled prospective study of complete steroid avoidance immunosuppressive protocol was undertaken in 10 unsensitized pediatric recipients (ages 5-21 years; mean 14.4 years) of first renal allografts, Steroids were substituted with extended daclizumab use, in combination with tacrolimus and mycophenolate mofetil, Protocol biopsies were performed in the steroid-free group at 0, 1, 3, 6, and 12 months posttransplantation, Clinical outcomes were compared to a steroid-based group of 37 matched historical controls. Results. Graft and patient survival was 100% in both groups. Clinical acute rejection was absent in the steroid-free group at a mean follow-up time of 9 months (range 3-13.7 months). Protocol biopsies in the steroid free group (includes 10 patients at 3 months, 7 sit 6 months, and 4 at 12 months) revealed only two instances of mild (Banff 1A) subclinical rejection (reversed by only a nominal increase in immunosuppression) and no chronic rejection. At 6 months the steroid-free group had no hypertension requiring treatment (P=0.003), no hypercholesterolemia (P=0.007), and essentially no body disfigurement (P=0.0001), Serum creatinines, Schwartz GFR, and mean delta height Z scores trended better in the steroid-free group. In the steroid-free group, one patient had cytomegalovirus disease wt 1 month and three had easily treated herpes simplex stomatitis, but with no significant increase in bacterial infections or rehospitalizations over the steroid-based group. The: steroid-free group was more anemic early posttransplantation (P=0.004), suggesting an early role of steroids in erythrogenesis; erythropoietin use normalized hematocrits by 6 months. Conclusions. Complete steroid-free immunosuppression :is efficacious and safe in this selected group of children with no early clinical acute rejection episodes. This protocol avoids the morbid side effects of steroids without increasing infection, and may play a future critical role in avoiding noncompliance, although optimizing renal function and growth.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 22 条
[1]  
Benfield M R, 1999, Pediatr Transplant, V3, P152, DOI 10.1034/j.1399-3046.1999.00011.x
[2]   Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. [J].
Birkeland, SA .
TRANSPLANTATION, 1998, 66 (09) :1207-1210
[3]   Hypertriglyceridemia in renal transplant recipients treated with sirolimus [J].
Brattström, C ;
Wilczek, HE ;
Tydén, G ;
Böttiger, Y ;
Säwe, J ;
Groth, CG .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (08) :3950-3951
[4]   GROWTH-RATE IN CHILDREN RECEIVING ALTERNATE-DAY CORTICOSTEROID TREATMENT AFTER KIDNEY-TRANSPLANTATION [J].
BROYER, M ;
GUEST, G ;
GAGNADOUX, MF .
JOURNAL OF PEDIATRICS, 1992, 120 (05) :721-725
[5]  
Bunchman T E, 2000, Pediatr Transplant, V4, P165, DOI 10.1034/j.1399-3046.2000.00109.x
[6]   Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience [J].
Dominguez, J ;
Mahalati, K ;
Kiberd, B ;
McAlister, VC ;
MacDonald, AS .
TRANSPLANTATION, 2000, 70 (08) :1244-1247
[7]   TRENDS IN THE USE OF GLUCOCORTICOIDS IN RENAL-TRANSPLANTATION [J].
HRICIK, DE ;
ALMAWI, WY ;
STROM, TB .
TRANSPLANTATION, 1994, 57 (07) :979-989
[8]  
IROBERTI I, 1994, CLIN TRANSPLANT, V8, P405
[9]   Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function - A report of the North American Pediatric Renal Transplant Cooperative Study [J].
Jabs, K ;
Sullivan, EK ;
Avner, ED ;
Harmon, WE .
TRANSPLANTATION, 1996, 61 (01) :31-36
[10]   Sirolimus: A new agent for clinical renal transplantation [J].
Kahan, BD .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :48-50